Compare Devon Energy Corp (DVN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Gilead Sciences, Inc. — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 3.4× Devon Energy Corp's market cap, and Devon Energy Corp pays the higher dividend (2.62%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and Gilead Sciences, Inc. for 111 Days on average.
| DVN | GILD | |
|---|---|---|
Market Cap | $53.81B | $182.40B |
Volume | 11,556,740 | 4,469,821 |
Sector | Energy | Health |
52-Week High | $52.07 | $155.80 |
52-Week Low | $31.74 | $116.74 |
Typical Hold Time | 136 Days | 111 Days |
Enterprise Value | $64.55B | $205.46B |
Dividend Yield | 2.62% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.92, up 2.17% today, with strong analyst support showing 72% buy ratings and a $62.53 consensus price target. The stock shows bullish technical momentum above key support levels, while fundamentals reveal solid profitability with 16.67% net margins and attractive valuation at 10.63 P/E. Recent activist pressure from Toms Capital for strategic alternatives and potential asset sales with BP creates near-term catalysts.
DVN presents compelling value with upside potential to analyst targets, though faces execution risks on asset sales and oil price volatility. The company's improving cash flow generation and Permian Basin focus support the bullish case, but investors should monitor activist developments and energy market conditions closely.
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
